Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury

Significance By catalyzing the destruction of cAMP and cGMP, cyclic nucleotide phosphodiesterases (PDEs) regulate their intracellular concentrations and biological actions. Eleven distinct gene families (PDE1–PDE11) define the PDE superfamily. Most families contain several PDE genes. Two separate but related genes generate PDE3 subfamilies PDE3A and PDE3B. Although inhibition of PDE3 protects rodent heart against ischemia/reperfusion (I/R) injury, the specific PDE3 isoform involved is undetermined. Using PDE3A- and PDE3B-KO mice, we report that deletion of PDE3B, but not PDE3A, protected mouse heart from I/R injury in vivo and in vitro, via cAMP-induced preconditioning. To our knowledge, our study is the first to define a role for PDE3B in cardioprotection against I/R injury and suggests PDE3B as a target for cardiovascular therapies. Although inhibition of cyclic nucleotide phosphodiesterase type 3 (PDE3) has been reported to protect rodent heart against ischemia/reperfusion (I/R) injury, neither the specific PDE3 isoform involved nor the underlying mechanisms have been identified. Targeted disruption of PDE3 subfamily B (PDE3B), but not of PDE3 subfamily A (PDE3A), protected mouse heart from I/R injury in vivo and in vitro, with reduced infarct size and improved cardiac function. The cardioprotective effect in PDE3B−/− heart was reversed by blocking cAMP-dependent PKA and by paxilline, an inhibitor of mitochondrial calcium-activated K channels, the opening of which is potentiated by cAMP/PKA signaling. Compared with WT mitochondria, PDE3B−/− mitochondria were enriched in antiapoptotic Bcl-2, produced less reactive oxygen species, and more frequently contacted transverse tubules where PDE3B was localized with caveolin-3. Moreover, a PDE3B−/− mitochondrial fraction containing connexin-43 and caveolin-3 was more resistant to Ca2+-induced opening of the mitochondrial permeability transition pore. Proteomics analyses indicated that PDE3B−/− heart mitochondria fractions were enriched in buoyant ischemia-induced caveolin-3–enriched fractions (ICEFs) containing cardioprotective proteins. Accumulation of proteins into ICEFs was PKA dependent and was achieved by ischemic preconditioning or treatment of WT heart with the PDE3 inhibitor cilostamide. Taken together, these findings indicate that PDE3B deletion confers cardioprotective effects because of cAMP/PKA-induced preconditioning, which is associated with the accumulation of proteins with cardioprotective function in ICEFs. To our knowledge, our study is the first to define a role for PDE3B in cardioprotection against I/R injury and suggests PDE3B as a target for cardiovascular therapies.

[1]  W. Shen,et al.  Regulation of Sarcoplasmic Reticulum Ca2+ ATPase 2 (SERCA2) Activity by Phosphodiesterase 3A (PDE3A) in Human Myocardium , 2015, The Journal of Biological Chemistry.

[2]  H. Ke,et al.  Advances in targeting cyclic nucleotide phosphodiesterases , 2014, Nature Reviews Drug Discovery.

[3]  Clint L. Miller,et al.  Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. , 2013, Journal of molecular and cellular cardiology.

[4]  N. Raghavachari,et al.  A role for phosphodiesterase 3B in acquisition of brown fat characteristics by white adipose tissue in male mice. , 2013, Endocrinology.

[5]  W. Shen,et al.  Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility Through Interacting With Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart , 2013, Circulation research.

[6]  P. Insel,et al.  Mitochondria‐localized caveolin in adaptation to cellular stress and injury , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  W. Catterall,et al.  Phosphoinositide 3-Kinase &ggr; Protects Against Catecholamine-Induced Ventricular Arrhythmia Through Protein Kinase A–Mediated Regulation of Distinct Phosphodiesterases , 2012, Circulation.

[8]  J. Perez-polo,et al.  Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus , 2012, Cardiovascular Drugs and Therapy.

[9]  John D. Scott,et al.  Anchoring Proteins as Regulators of Signaling Pathways , 2012, Circulation research.

[10]  S. Ishikawa,et al.  Role of connexin-43 in protective PI3K-Akt-GSK-3β signaling in cardiomyocytes. , 2012, American journal of physiology. Heart and circulatory physiology.

[11]  M. Gucek,et al.  Acute inhibition of GSK causes mitochondrial remodeling. , 2012, American journal of physiology. Heart and circulatory physiology.

[12]  V. Manganiello,et al.  Phosphodiesterase 3A (PDE3A) Deletion Suppresses Proliferation of Cultured Murine Vascular Smooth Muscle Cells (VSMCs) via Inhibition of Mitogen-activated Protein Kinase (MAPK) Signaling and Alterations in Critical Cell Cycle Regulatory Proteins* , 2011, The Journal of Biological Chemistry.

[13]  S. Heymans,et al.  Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. , 2011, Molecular cell.

[14]  M. Ruiz-Meana,et al.  The SR-mitochondria interaction: a new player in cardiac pathophysiology. , 2010, Cardiovascular research.

[15]  Wenjun Xie,et al.  Cardioprotection of Ischemia/Reperfusion Injury by Cholesterol-Dependent MG53-Mediated Membrane Repair , 2010, Circulation research.

[16]  ZhengChen,et al.  Cardioprotection of Ischemia/Reperfusion Injury by Cholesterol-Dependent MG53-Mediated Membrane Repair , 2010 .

[17]  Xianhua Wang,et al.  MG53 Constitutes a Primary Determinant of Cardiac Ischemic Preconditioning , 2010, Circulation.

[18]  Y. Yamasaki,et al.  The Phosphodiesterase Inhibitor Cilostazol Induces Regression of Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus: Principal Results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) Study: A Randomized Trial , 2010, Circulation.

[19]  W. Lederer,et al.  Excitation-contraction coupling changes during postnatal cardiac development. , 2010, Journal of molecular and cellular cardiology.

[20]  P. Strålfors,et al.  Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. , 2009, The Biochemical journal.

[21]  R. Mangiafico,et al.  Current management of intermittent claudication: the role of pharmacological and nonpharmacological symptom-directed therapies. , 2009, Current vascular pharmacology.

[22]  S. Sollott,et al.  Role of Glycogen Synthase Kinase-3β in Cardioprotection , 2009, Circulation research.

[23]  H. Kawashima,et al.  Local control of mitochondrial membrane potential, permeability transition pore and reactive oxygen species by calcium and calmodulin in rat ventricular myocytes. , 2009, Journal of molecular and cellular cardiology.

[24]  Y. Sunada,et al.  Membrane Repair Defects in Muscular Dystrophy Are Linked to Altered Interaction between MG53, Caveolin-3, and Dysferlin*◆ , 2009, The Journal of Biological Chemistry.

[25]  G. Heusch,et al.  Presence of connexin 43 in subsarcolemmal, but not in interfibrillar cardiomyocyte mitochondria , 2009, Basic Research in Cardiology.

[26]  G. Hajnóczky,et al.  MAM: more than just a housekeeper. , 2009, Trends in cell biology.

[27]  P. Insel,et al.  Membrane rafts and caveolae in cardiovascular signaling , 2009, Current opinion in nephrology and hypertension.

[28]  P. Insel,et al.  Cardiac-Specific Overexpression of Caveolin-3 Induces Endogenous Cardiac Protection by Mimicking Ischemic Preconditioning , 2008, Circulation.

[29]  Anindita Das,et al.  Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β* , 2008, Journal of Biological Chemistry.

[30]  P. dos Santos,et al.  Conditioning the heart induces formation of signalosomes that interact with mitochondria to open mitoKATP channels. , 2008, American journal of physiology. Heart and circulatory physiology.

[31]  M. Miyazaki,et al.  6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (Cilostazol), a Phosphodiesterase Type 3 Inhibitor, Reduces Infarct Size via Activation of Mitochondrial Ca2+-Activated K+ Channels in Rabbit Hearts , 2008, Journal of Pharmacology and Experimental Therapeutics.

[32]  E. Murphy,et al.  Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. , 2008, Physiological reviews.

[33]  P. Insel,et al.  Caveolae as organizers of pharmacologically relevant signal transduction molecules. , 2008, Annual review of pharmacology and toxicology.

[34]  P. Backx,et al.  PI3K&ggr; Is Required for PDE4, not PDE3, Activity in Subcellular Microdomains Containing the Sarcoplasmic Reticular Calcium ATPase in Cardiomyocytes , 2007, Circulation research.

[35]  Yongge Liu,et al.  Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. , 2007, Cellular signalling.

[36]  Renzhi Han,et al.  Dysferlin and muscle membrane repair. , 2007, Current opinion in cell biology.

[37]  D. McAdoo,et al.  The Cardioprotective Effect of a Statin and Cilostazol Combination: Relationship to Akt and Endothelial Nitric Oxide Synthase Activation , 2007, Cardiovascular Drugs and Therapy.

[38]  D. Cooper,et al.  Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. , 2007, Physiological reviews.

[39]  Manuela Zaccolo,et al.  of in The Role of the in the A Molecular for Generating cAMP and cGMP Signaling Cross-Talk Role of Phosphodiesterases and Implications for Cardiac Pathophysiology , 2007 .

[40]  E. Degerman,et al.  Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. , 2007, The Biochemical journal.

[41]  K. Sumikawa,et al.  Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion , 2007, Journal of Anesthesia.

[42]  Clint L. Miller,et al.  Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart , 2007, Circulation research.

[43]  F. Sundler,et al.  Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. , 2006, The Journal of clinical investigation.

[44]  R. Fischmeister,et al.  Compartmentation of Cyclic Nucleotide Signaling in the Heart The Role of Cyclic Nucleotide Phosphodiesterases , 2006 .

[45]  W. Weintraub,et al.  Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. , 2006, American heart journal.

[46]  M. Chiariello,et al.  Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. , 2006, Vascular pharmacology.

[47]  G. Heusch,et al.  Translocation of Connexin 43 to the Inner Mitochondrial Membrane of Cardiomyocytes Through the Heat Shock Protein 90–Dependent TOM Pathway and Its Importance for Cardioprotection , 2006, Circulation research.

[48]  V. Manganiello,et al.  Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium* , 2005, Journal of Biological Chemistry.

[49]  G. Heusch,et al.  Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. , 2005, Cardiovascular research.

[50]  H. Nakaya,et al.  Mitochondrial Ca2+-Activated K+ Channels in Cardiac Myocytes: A Mechanism of the Cardioprotective Effect and Modulation by Protein Kinase A , 2005, Circulation.

[51]  C. Parent.  Faculty Opinions recommendation of PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. , 2004 .

[52]  L. Silengo,et al.  PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.

[53]  Chengyu Liu,et al.  Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. , 2004, The Journal of clinical investigation.

[54]  E. Olson,et al.  Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore , 2004 .

[55]  John D. Scott,et al.  AKAP mediated signal transduction. , 2003, Annual review of pharmacology and toxicology.

[56]  Nicholas J. Hoogenraad,et al.  Molecular Chaperones Hsp90 and Hsp70 Deliver Preproteins to the Mitochondrial Import Receptor Tom70 , 2003, Cell.

[57]  Yongge Liu,et al.  Cytoprotective Role of Ca2+- Activated K+ Channels in the Cardiac Inner Mitochondrial Membrane , 2002, Science.

[58]  V. Manganiello,et al.  Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3A in Cardiac Myocytes* , 2002, The Journal of Biological Chemistry.

[59]  Yongge Liu,et al.  Comparison of the Effects of Cilostazol and Milrinone on cAMP-PDE Activity, Intracellular cAMP and Calcium in the Heart , 2002, Cardiovascular Drugs and Therapy.

[60]  F. Salloum,et al.  Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. , 2002, American journal of physiology. Heart and circulatory physiology.

[61]  E. Murphy,et al.  Phosphorylation of Glycogen Synthase Kinase-3&bgr; During Preconditioning Through a Phosphatidylinositol-3-Kinase–Dependent Pathway Is Cardioprotective , 2002, Circulation research.

[62]  M. Hori,et al.  Cardioprotective Effect Afforded by Transient Exposure to Phosphodiesterase III Inhibitors: The Role of Protein Kinase A and p38 Mitogen-Activated Protein Kinase , 2001, Circulation.

[63]  L. Brunton,et al.  Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. , 2001, Annual review of pharmacology and toxicology.

[64]  I. Nonaka,et al.  Caveolin-3 deficiency causes muscle degeneration in mice. , 2000, Human molecular genetics.

[65]  R. Parton,et al.  Caveolin-3 Associates with Developing T-tubules during Muscle Differentiation , 1997, The Journal of cell biology.

[66]  M. Lisanti,et al.  Expression of Caveolin-3 in Skeletal, Cardiac, and Smooth Muscle Cells , 1996, The Journal of Biological Chemistry.

[67]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[68]  J. Knittel,et al.  Membrane Cholesterol Dynamics: Cholesterol Domains and Kinetic Pools , 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[69]  R. Jennings,et al.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. , 1986, Circulation.

[70]  C. Hoppel,et al.  Heterogeneous response of subsarcolemmal heart mitochondria to calcium. , 1986, The American journal of physiology.

[71]  J. Perez-polo,et al.  Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. , 2013, American journal of physiology. Heart and circulatory physiology.

[72]  P. Fisher,et al.  Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection. , 2008, Journal of molecular and cellular cardiology.

[73]  P. Insel,et al.  Caveolin-3 expression and caveolae are required for isoflurane-induced cardiac protection from hypoxia and ischemia/reperfusion injury. , 2008, Journal of molecular and cellular cardiology.

[74]  A. Szewczyk,et al.  [Mitochondrial ion channels]. , 2002, Postepy higieny i medycyny doswiadczalnej.

[75]  E. Olson,et al.  Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. , 2004, The Journal of clinical investigation.

[76]  E. Degerman,et al.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. , 2001, Progress in nucleic acid research and molecular biology.